FDA Inspection 1158806 — Novartis Pharmaceutical Corporation

Novartis Pharmaceutical Corporation — FEI 3008977933

The FDA completed an inspection of Novartis Pharmaceutical Corporation on Nov 19, 2021 in Indianapolis, IN. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Nov 19, 2021
Fiscal Year
2022
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Indianapolis, IN (United States)

Additional Details

Sponsor, Contract Research Organization